Your browser doesn't support javascript.
loading
MYB immunohistochemistry as a predictor of MYB::NFIB fusion in the diagnosis of adenoid cystic carcinoma of the head and neck.
Klein Nulent, Thomas J W; van Es, Robert J J; Breimer, Gerben E; Valstar, Matthijs H; Smit, Laura A; Speksnijder, Caroline M; de Bree, Remco; Willems, Stefan M.
Afiliación
  • Klein Nulent TJW; Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Oral and Maxillofacial Surgery, Haaglanden Medical Center, The Hague, The Netherlands; Department of Oral and Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, T
  • van Es RJJ; Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Oral and Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Breimer GE; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Valstar MH; Department of Head and Neck Oncology and Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Smit LA; Department of Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Speksnijder CM; Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • de Bree R; Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Willems SM; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands.
Oral Surg Oral Med Oral Pathol Oral Radiol ; 2024 Aug 16.
Article en En | MEDLINE | ID: mdl-39218775
ABSTRACT

OBJECTIVES:

Diagnosing adenoid cystic carcinoma (AdCC) is challenging due to histopathological variability and similarities with other tumors. In AdCC pathogenesis, the cellular myeloblastosis gene (c-MYB) often exhibits a MYBNFIB fusion from a reciprocal translocation. This study aimed to assess the predictive accuracy of MYB immunohistochemistry for detecting this translocation compared to fluorescence in situ hybridization (FISH). STUDY

DESIGN:

This study included 110 AdCC patients (1999-2017) from two Dutch head and neck centers using tissue microarrays and full slides. Median MYB expression levels by immunohistochemistry were compared based on translocation status by FISH, and differences within clinicopathological parameters were examined. An immunohistochemical cut-off was established to estimate the translocation.

RESULTS:

MYB immunohistochemistry was available in 90/110 patients, with a median expression of 27%. FISH was interpretable in 79/108 tumors, identifying MYBNFIB fusion in 44 (56%). Among 62 patients with both MYB expression and translocation data, the fusion was present in 38 (61%). These tumors had higher MYB expression (30%) than nontranslocated tumors (6%); P = .02. A 60% MYB expression cut-off yielded 100% specificity for detecting the translocation but had no prognostic value.

CONCLUSIONS:

Although MYB protein expression alone lacks diagnostic precision, protein expression >60% predicted the MYBNFIB fusion in all tumors.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oral Surg Oral Med Oral Pathol Oral Radiol Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oral Surg Oral Med Oral Pathol Oral Radiol Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos